Search

Leveraging AI for more reliable predictions of immunotherapy in lung cancer | News | CORDIS | European Commission

AI tools improve prediction of immunotherapy outcomes in advanced NSCLC by integrating multimodal data; the EU-backed I3LUNG study shows AI-assisted decision support outperforms current biomarkers and benefits non-expert physicians, with a large, diverse patient cohort and a goal of explainable, scalable precision immunotherapy.

Anthropics's Claude AI Helped Boosting Cancer-Fighting Cells in Lab Tests

Claude AI assisted cancer-immunotherapy design and manufacturing review, reducing time and increasing receptor density, with results from multiple partners; potential expansion of multi-function cell therapies, though some findings remain exploratory and AI-assisted rather than fully validated.

Anthropic CEO Shocks: “Cancer Will Be a Thing of the Past Thanks to AI.”

Translated title. Original: Generální ředitel společnosti Anthropic šokuje: „Rakovina bude díky umělé inteligenci minulostí.“

Anthropic is using AI to support research into cancer treatments, food allergies and rare diseases. Early results are preclinical, and any candidates must still prove safe and effective in human trials, despite CEO Dario Amodei’s prediction that cancer could be overcome within 10 years.

AI is changing cancer treatment — and a new breakthrough shows just how far we've come | Tom's Guide

AI tools are helping researchers analyze tumor differences, predict drug responses and speed early drug research. A Phase 3 trial found that a personalized melanoma vaccine combined with Keytruda reduced recurrence or death risk, though the vaccine is not FDA-approved.

Micron beat, Nvidia distancing: Moderna stock with incredible annual performance – and now? - DER AKTIONÄR

Translated title. Original: Micron geschlagen, Nvidia distanziert: Moderna-Aktie mit unglaublicher Jahresperformance – und nun? - DER AKTIONÄR

Moderna has led stock gains amid AI-driven market strength, outpacing peers like Micron and Nvidia. The company’s mRNA vaccines and expanding pipeline, including oncology and rare diseases, drive investor interest ahead of its November 6 earnings, with potential updates on influenza vaccines and oncology prospects detailed in AKTIONÄR 45/2026.

AI in oncology, how to choose technologies useful to patients - Agenda Digitale

Translated title. Original: AI in oncologia, come scegliere tecnologie utili ai pazienti - Agenda Digitale

AI enhances oncology through large-scale data analysis for therapy targeting and patient care, but translating findings into real patient benefits requires rigorous validation. The document reports on a conference in Salerno discussing precision medicine, pain management, safety, and telemedicine, with studies on multi-omics AI approaches and AI-assisted cancer diagnosis and pain assessment.

Coherence raises USD $45 million for cancer implant

Coherence has secured $45 million in Series A funding led by Founders Fund and The OpenAI Startup Fund to advance an implantable brain-computer interface for cancer. The company aims to monitor and treat glioblastoma by recording electrical biomarkers and delivering real-time therapy, with early human testing underway in Australia and FDA regulatory activities forthcoming.

Anthropic uses AI Claude in cancer drug research: preclinical results and a forecast for the next 10 years.

Translated title. Original: Anthropic gebruikt AI Claude in onderzoek naar kankermedicijnen: preklinische resultaten en een prognose voor de komende 10 jaar.

Anthropic reports early preclinical work using Claude to support research into cancer, food allergies and rare childhood muscle diseases. The results may help researchers screen candidates faster, but any treatments must still pass human trials and extensive testing.

CAR T-cell safety, Sjögren’s pipeline to headline ACR Convergence

ACR Convergence 2026 in Orlando will feature data on CAR T-cell safety, Sjögren’s disease, and other rheumatic topics, with emphasis on AI, GLP-1 therapies, and cost considerations. Healio Rheumatology gathers expert perspectives on sessions, safety, and the evolving landscape of cellular therapies amid recent safety concerns.

Anthropic expands Claude's role to drug development

Anthropic reports its Claude AI is being expanded to aid drug discovery and development with partners, showing promising preclinical results in antibody design, CAR-T signaling domains, and process efficiencies, while stressing the need for validation, oversight, and human expertise as work remains preclinical.